Basic Study

Transcription factor glucocorticoid modulatory element-binding protein 1 promotes hepatocellular carcinoma progression by activating Yes-associate protein 1

Chen C et al. GMEB1 promotes HCC progression by activating YAP1

Cheng Chen, Hai-Guan Lin, Zheng Yao, Yi-Ling Jiang, Hong-Jin Yu, Jing Fang, Wei-Na Li

Abstract

BACKGROUND
Glucocorticoid modulatory element-binding protein 1 (GMEB1), which has been identified as a transcription factor, is a protein widely expressed in various tissues. Reportedly, the dysregulation of GMEB1 is linked to the genesis and development of multiple cancers.

AIM
To explore GMEB1’s biological functions in hepatocellular carcinoma (HCC) and figuring out the molecular mechanism.

METHODS
GMEB1 expression in HCC tissues was analyzed employing the StarBase database. Immunohistochemical staining, Western blotting and quantitative real-time PCR were conducted to examine GMEB1 and Yes-associate protein 1 (YAP1) expression in HCC cells and tissues. Cell counting kit-8 assay, Transwell assay and flow cytometry were
utilized to examine HCC cell proliferation, migration, invasion and apoptosis, respectively. The JASPAR database was employed for predicting the binding site of GMEB1 with YAP1 promoter. Dual-luciferase reporter gene assay and chromatin immunoprecipitation-qPCR were conducted to verify the binding relationship of GMEB1 with YAP1 promoter region.

RESULTS

GMEB1 was up-regulated in HCC cells and tissues, and GMEB1 expression was correlated to the tumor size and TNM stage of HCC patients. GMEB1 overexpression facilitated HCC cell multiplication, migration, and invasion, and suppressed the apoptosis, whereas GMEB1 knockdown had the opposite effects. GMEB1 bound to YAP1 promoter region and positively regulated YAP1 expression in HCC cells.

CONCLUSION

GMEB1 facilitates HCC malignant proliferation and metastasis by promoting the transcription of the YAP1 promoter region.

**Key Words:** Hepatocellular carcinoma; Glucocorticoid modulatory element-binding protein 1; Yes-associate protein 1; Apoptosis; Proliferation


**Core Tip:** Glucocorticoid modulatory element-binding protein 1 (GMEB1) was highly expressed in hepatocellular carcinoma (HCC) tissues. Functionally, GMEB1 modulates the malignant biological behaviors of HCC cells. Mechanistically, GMEB1 promotes the expression of Yes-associate protein 1 at transcriptional level. In short, the present study suggested that for HCC, GMEB1 might be a diagnostic biomarker and treatment target.
INTRODUCTION

Liver cancer is the third leading cause of cancer-related deaths worldwide, with more than 780,000 deaths due to liver cancer in 2018. Approximately 90% of liver cancer cases originate in hepatocytes and are referred to as hepatocellular carcinoma (HCC)\(^1\). HCC is the fifth most common cancer in males and the ninth most common cancer in females, with an estimated 500,000 and 200,000 new cases annually in the world, respectively. The pathogenesis of hepatocellular carcinoma is complicated by structural mutations in the proto-oncogene and the addition of exogenous pathogenic factors such as viruses, excessive alcohol consumption, obesity and aflatoxins, which have contributed to the development of HCC\(^2,3\). Therefore, HCC is one of the most common types of clinical malignancies in the digestive system, and it also ranks fourth among the causes of cancer death globally\(^4\). Currently, the predominant treatment options for HCC include surgical resection, liver transplantation, radiotherapy and chemotherapy\(^5\). Nevertheless, most HCC cases have already been in an intermediate to advanced stage at diagnosis, missing the optimal time for surgical treatment\(^6\). Besides, the high cost and huge shortage of donors greatly limit the clinical application of liver transplantation\(^7,8\). In this context, it is necessary to identify more reliable early diagnostic markers for HCC diagnosis and to discover more effective new therapeutic targets for clinical intervention, thus providing new insights to improve the prognosis and overall survival rate of HCC patients.

Glucocorticoid modulatory element-binding protein 1 (GMEB1) is a nucleoprotein with a molecular weight of 88 kDa, and can interact with GMEB2 and bind with the glucocorticoid regulatory element (GME) of the tyrosine aminotransferase (TAT) gene promoter sequence, thereby regulating the glucocorticoid receptor transactivation\(^9\). It has been demonstrated that IL-2 can inhibit glucocorticoid-induced T-cell apoptosis by boosting GMEB1 expression and activating the PI3K/AKT pathway\(^10\), which is a preliminary indication of the anti-apoptotic function of GMEB1. Meanwhile, FOXL2 is an important transcription factor involved in the transcriptional regulation of several
target genes, and GMEB1 was found to bind to FOXL2, whose interaction with FOXL2 could regulate the apoptotic process of cells\textsuperscript{[11]}. Additionally, GMEB1 can also bind to pro-caspases and repress its activation and apoptosis\textsuperscript{[12,13]}. Given that tumor development cannot occur without uncontrolled cell proliferation and apoptotic escape, the anti-apoptotic effect of GMEB1 has prompted researchers to explore the relevance of GMEB1 dysregulation to tumorigenesis and development. For example, GMEB1 suppresses CASP8 activation via regulating CFLAR\textsubscript{6} ubiquitination and degradation to repress the cellular apoptosis and thereby promoting malignant progression of non-small cell lung cancer\textsuperscript{[9]}. Except from that, abnormally high GMEB1 expression in colorectal cancer (CRC) has been validated to be associated with increased lymph node invasion, poor TNM staging and reduced differentiation in CRC, and through mechanistic study, researchers further identified GMEB1 as a direct target gene of miR-320a, which negatively regulates GMEB1 expression, resulting in the inhibition of EMT, which is the prelude to CRC cell invasion and migration\textsuperscript{[14]}. Additional bioinformatics studies have further shown that high expression of several transcription factors, including GMEB1, is a promising biomarker and/or therapeutic target for prostate cancer\textsuperscript{[15]}. Thus, it becomes clear that GMEB1 can contribute to malignant progression in various tumor types through different mechanisms. Nonetheless, the expression of GMEB1 in HCC and the molecular mechanism to promote the malignant evolution of HCC have not been elucidated.

Yes-associate protein 1 (YAP1) is one of the prime effector proteins downstream of the Hippo pathway, which controls organ size, normal tissue homeostasis and stem cell function through modulating cell proliferation and apoptosis\textsuperscript{[16]}. YAP1 has been proved to play an important role as an oncprotein in a variety of tumors. For example, in clinical specimens, YAP has been reported to be overexpressed and overactivated after nucleation in prostate, colon, breast and non-small cell lung cancers, as well as ovarian and hepatocellular carcinomas\textsuperscript{[17-20]}, significantly contributing to the development and progression of these tumors. More importantly, in studies surrounding the pathogenesis of HCC, there is a growing consensus that abnormalities in the Hippo
signaling pathway are closely associated with the development of HCC. The abnormal expression and dysfunction of YAP1, a key protein in the Hippo signaling pathway, is directly related to the malignant progression of HCC. A clinical study including 177 HCC patients further indicated that YAP1 was an independent prognostic marker significantly associated with shorter disease-free and overall survival in hepatocellular carcinoma. Currently, the mechanisms underlying the promotion of tumor progression by YAP1 revolve around the binding of YAP1 to the transcription factor TEAD, which in turn initiates the transcription of many genes involved in cell proliferation and survival, including downstream target genes such as BIRC5, CTGF and Cyclin D1. However, as research has continued, the upstream proteins that regulate YAP1 have been further identified. In addition to the classical upstream LATS1/2 that regulates YAP1 expression, it has been reported that, for example, the transcription factor FOXM1 promotes the proliferation, migration and invasion of breast cancer cells through promoting YAP1 transcription activation. Furthermore, in HCC, SIX4 can promote cell metastasis by upregulating YAP1 and c-MET.

Could GMEB1, a transcription factor closely associated with tumor development, also promote the malignant progression of HCC by regulating the transcription of YAP1 and thus affecting the normal function of the Hippo signaling pathway? With this question in mind, we would like to confirm the potential regulatory relationship between GMEB1 and YAP1 in this study, thus providing a new intervention target for the Hippo signaling pathway, a key signaling pathway in HCC pathogenesis. To this end, we will firstly focus on examining the expression of GMEB1 in human HCC tissues and HCC cell lines, and clarifying the regulatory mechanism of the interaction between GMEB1 and YAP1 in promoting HCC progression in this study. We hope that our study will reveal the crucial role of GMEB1 in the development of HCC, explore the additional biological functions of GMEB1, and provide new therapeutic strategies for the clinical treatment of patients with HCC accompanied with YAP1 overexpression.

MATERIALS AND METHODS
Case collection
With the approval of Zhejiang Xiaoshan Hospital’s Ethics Committee, cancerous tissues and their corresponding para-cancerous tissues from 55 patients with HCC previously admitted to our hospital were selected for this study. Immediately after surgical removal, the tissues were frozen at -196 °C and kept at -80 °C until use. The clinical data and clinicopathological data of all subjects were complete, and none of them underwent preoperative chemotherapy or radiotherapy.

Immunohistochemistry
We fixed the cancerous and normal para-cancerous tissues in 10% formaldehyde and embedded them in paraffin. Afterwards, the tissues were cut into 4-μm-thick slices, deparaffinized with xylene, and washed with PBS. The antigen retrieval was induced by heat in PBS (microwave heating, 96 °C, 15 min), and then the tissues were treated with 3% H₂O₂ for removing endogenous peroxidases. The slices were incubated with citrate buffer to repair the antigen, and blocked with 5% bovine serum albumin (Sangon Biotech Co., Ltd., Shanghai, China) at 4 °C for 30 min. The slices were incubated at 4 °C overnight with the primary antibody GMEB1 (ab240646, 1:100, Abcam, Cambridge, United Kingdom) and then with horseradish peroxidase-conjugated secondary antibody (1:5000, ab6721, Abcam) for 30 min at room temperature. The sections were stained with diaminobenzidine (Sigma-Aldrich, St. Louis, MO, United States) at room temperature for 10 min. Ultimately, the slices were counter-stained with hematoxylin and sealed and fixed with PerMount (BIOS, Beijing, China). Eventually, the slices were observed and photographed under an optical microscope (Olympus Optical Company, Tokyo, Japan).

As previously mentioned, the staining signals were scored by the percentage of positive tumor cells and staining intensity[28]. The grading of the positive tumor cell ratio is as follows: 0% (0 point), 0.01%-25% (1 point), 25.01%-50% (2 points), 50.01%-75% (3 points) and ≥ 75% (4 points). The degree of staining intensity: no staining (0 point), weak staining (1 point), medium staining (2 points) and strong staining (3 points). The
following formula was adopted to calculate the immunohistochemistry (IHC) score of each section: IHC score = staining intensity × percentage of positively stained tumor cells. The total score is 0-12 points. The score > 4 was defined as high expression, while the score ≤ 4 was defined as low expression.

Cell culture and transfection
From the Chinese Center for Type Culture Collection (Wuhan, China), we bought human HCC cell lines (HepG2, HCCLM3, Huh7 and MHCC97H) and human-derived liver cell line (HL-7702). All cells were cultured in RPMI-1640 medium (Thermo Fisher Scientific, Carlsbad, MA, United States) with 10% fetal bovine serum (Thermo Fisher Scientific, Waltham, MA, United States) and 100 μg/mL streptomycin and 100 U/mL penicillin (Invitrogen, Carlsbad, CA, United States) at 37 °C in 5% CO₂. From GenePharma Co., Ltd. (Shanghai, China), we purchased pcDNA-GMEB1, pcDNA empty vector (NC), small interfering RNA (siRNA) negative control (si-NC), siRNAs against GMEB1 (si-GMEB1#1 and si-GMEB1#2), pcDNA-YAP1 and siRNA against YAP1 (si-YAP1). HepG2 and Huh7 cells were transfected employing Lipofectamine® 3000 (Invitrogen, Carlsbad, CA, United States) under the supplier’s instructions. At 48 h after transfection, Western blot was conducted to verify the transfection efficiency.

Lentiviral infection
The lentiviral overexpression vector pCDH-CMV-MCS-EF1-Puro and the shRNA vector pLKO.1-puro were purchased from GenScript Biotech. The HCC cell line HepG2 was inoculated in 6-well cell culture plates with 2 mL of medium containing 10% fetal bovine serum 1 d prior to the infection and incubated in a constant temperature incubator at 37 °C with 5% CO₂. The lentivirus was transfected when the cell density reached 80%. An appropriate amount of lentivirus was added to the cell culture plate according to the MOI (multiplicity of infection) = 5 and incubated overnight at 37 °C with 5% CO₂. Change to fresh medium 24 h after infection. The puromycin was added 36 h after infection to allow the cells infected with the puromycin resistance gene to
proliferate sufficiently. 72 h later the puromycin medium was withdrawn and the remaining cells continued to be cultured to obtain stable overexpression or silenced cell lines.

**Quantitative real-time PCR**

TRIzol reagent (Invitrogen, Carlsbad, CA, United States) was utilized to extract total RNA from tissues and cells, and the RNA purity and concentration were determined by UV absorption method. Subsequently, a PrimeScript-RT Kit (Takara, Shiga, Japan) was employed for synthesizing complementary DNA (cDNA) from 1 μg of total RNA under the manufacturer's protocol, and then ABI7300 Real-Time PCR System (Applied Biosystems, Foster City, CA, United States) and SYBR® Premix Ex Taq™ (TaKaRa, Dalian, China) were used for quantitative real-time PCR (qRT-PCR). All fluorescence data were converted to relative quantification, and the 2^{-ΔΔCT} method was utilized to calculate the relative expression, with GAPDH as the internal control. GMEBI primer sequence: forward, 5'-GCACCAAAUUUGAUCUUCU-3', reverse, 5'-GCACACACAUUUUGCCUUAA-3'; YAP1 primer sequence: forward, 5'-CCCTCGTTTTGCCATGAACC-3', reverse, 5'-GTTGCTGCTGGTGAGGTTG-3'; GAPDH primer sequence: forward, 5'-CGACACTTATCATGGCTA-3', reverse, 5'-TGTGGCGATCAGTGAAT-3'.

**Western blot analysis**

The cells were harvested and incubated with pre-cooled radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime, Shanghai, China) for 20 min on ice. We collected the supernatant following centrifuging the cell lysis solution for 20 min at 13000 r/min at 4 °C. Then, a BCA protein quantification kit was utilized to measure the concentration of protein. The protein was isolated by 12% SDS-PAGE, and transferred onto a polyvinylidene difluoride membrane. After being blocked with Tris-buffered saline Tween (TBST) solution containing 3% bovine serum albumin at room temperature for 1 h, the membrane was incubated overnight with diluted primary
antibodies at 4 °C: anti-GMEB1 antibody (Abcam, 1:1000, ab240646), anti-GAPDH antibody (1:1000, Abcam, ab8245), and anti-YAP1 antibody (1:1000, Abcam, ab52771). The membrane was washed 5 times with TBST, 3 min for each time. Then, the membrane and the added diluted secondary antibody (1:5000, Abcam, ab6721) were incubated at room temperature for 40 min. The protein bands were observed employing the ECL Western blot kit (Beyotime, Shanghai, China). ImageJ software (NIH, Bethesda, MD, United States) was adopted for analyzing each band’s gray value, and the ratio of the target protein’s gray value to that of GAPDH functioned as the relative protein expression for analysis.

**Cell proliferation assay**

Cell Counting Kit-8 (CCK-8) (Beyotime, Shanghai, China) was employed for detecting cell proliferation. HepG2 and Huh7 cells during logarithmic growth were taken and inoculated into 96-well plates (5 × 10^3 cells/well), which were incubated in a 37 °C, 5% CO₂ incubator for 1, 2 and 3 days, respectively. After that, 10 μL of CCK-8 reagent was added to each well and incubated for 2 h at 37 °C. We discarded the supernatant, and used an automatic microplate reader (Bio-Rad, Hercules, CA, United States) to determine the absorbance (OD) value at 450 nm of each well.

**Transwell assays**

Matrigel (BD Biosciences, Franklin Lakes, NJ, United States) preserved at -20 °C was melted at 4 °C overnight and mixed with serum-free medium. 100 μL of the medium was pipetted into the upper Transwell chamber, which was then let stand for 5 h at 37 °C. HepG2 and Huh7 cells were collected to prepare single-cell suspension with a density of 5 × 10^5 cells/mL. 500 μL of 10% fetal bovine serum-containing medium was added to the lower compartment, and 200 μL of cell suspension was added to the top compartment. The Transwell chamber was incubated at 37 °C for 48 h. We wiped off the remaining cells and Matrigel carefully. The migrated cells in the lower compartment were fixed with 4% formaldehyde at room temperature for 30 min and stained with
crystal violet for 20 min at room temperature. The cells in 5 random views were photographed and counted under the inverted microscope (Nikon, Tokyo, Japan). In the migration assay, Matrigel was not added to the top compartment of Transwell, and the rest was as same as that in the invasion assay.

**Flow cytometry**
Cell apoptosis was detected via the Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis detection kit (Southern Biotechnology, Birmingham, Al, United States). Huh7 and HepG2 cells 48 h after transfection were trypsinized and collected and inoculated into 6-well plates. The cell density was adjusted to $2 \times 10^4$ cells/well, and the culturing was continued for 24 h. After washing with precool PBS twice, the cells were re-suspended in 1×Binding buffer. We added 5 μL of PI and 5 μL of Annexin V-FITC to the cell suspension, which was subsequently mixed fully and incubated for 15 min at room temperature away from light. Afterwards, under the requirements of the instructions, the apoptosis was detected by the flow cytometer (BD Biosciences, San Jose, CA, United States) within 1 h.

**Dual-luciferase reporter gene assay**
We employed the JASPR database (http://jaspar.genereg.net/) for predicting the binding sites of GMEB1 to YAP1 promoter region. The target fragments of mutant YAP1 and wild-type YAP1 were established and inserted into the pGL3 vector (Promega, Madison, WI, United States) to construct pGL3-YAP1-mutant (YAP1-MUT) and pGL3-YAP1-wild type (YAP1-WT) reporter vectors. YAP1-MUT or YAP1-WT and pcDNA-GMEB1 overexpression plasmids or si-GMEB1#1 were cotransfected into HepG2 and Huh7 cells. The luciferase activity was measured 48 h after transfection with the Dual-Luciferase Reporter Assay system (Promega, Madison, WI, United States) under the instructions.

**Chromatin immunoprecipitation assay**
A EZ-ChIP™ kit (Millipore, Billerica, MA, United States) was adopted for performing chromatin immunoprecipitation (ChIP) assay. About $1 \times 10^7$ HepG2 and Huh7 cells were cross-linked at 37 °C for 10 min in 1% formaldehyde, and reacted with 125 mmol/L glycine solution at room temperature for 5 min. The mixture was sonicated on ice, 15 s each time, and 15 times at 15-second intervals. Following that, the sonicated product was centrifuged for 10 min at 4 °C at 12000 g. The supernatant was harvested, divided into two tubes, and was incubated with negative control IgG antibody (Abcam, ab6721) or GMEB1 antibody (Abcam, ab240646) at 4 °C overnight. Next, protein agarose/agarose gel was utilized to precipitate DNA-protein complexes which were then centrifuged for 5 min at 12000 g at 4 °C. Subsequently, the cross-linking was reversed at 65 °C overnight, and DNA fragments were recovered after extraction and purification by phenol/chloroform. Eventually, the binding of GMEB1 with YAP1 promoter region and YAP1 specific primers was detected via qRT-PCR.

**Ballyc nude mouse subcutaneous transplantation tumour model**

5-6 wk C57BL/6 mice (purchased from Beijing Viton Lever Laboratory Animal Technology Co., Ltd.) were housed under pathogenic conditions at 26-28 °C and 50-65% humidity. All animal experiments conformed to ethical norms and were approved by the animal ethics committee of our institution. To construct subcutaneous tumors, sh-NC (shRNA negative control), sh-GMEB1, oe-NC (overexpression negative control), oe-YAP1, sh-GMEB1+oe-YAP1 cells were suspended in 100 μL PBS diluted in Matrigel matrix gel (356234, Corning) in quantities of $1 \times 10^6$ (PBS:Matrigel = 2:1), cells were injected subcutaneously into the right axilla of mice ($n = 5$/group) and tumor size was measured every 3 days. Tumor volume was calculated using the formula: $V = (L \times W^2)/2$, where V is the volume (mm$^3$), L is the long diameter and W is the short diameter. Transplanted tumors were taken from Balb/c nude mice after 30 d for subsequent experiments.

To examine the effect on metastatic capacity, sh-NC (shRNA negative control), sh-GMEB1, oe-NC, oe-YAP1, sh-GMEB1+ oe-YAP1 cells were injected into nude mice ($n = \ldots$)
5/group) via tail vein at an amount of $1 \times 10^5$, respectively. Mice were executed 60 days after injection, and number of metastatic foci on the lungs of each group were counted.

**Statistical analysis**

SPSS22.0 statistical software was employed to carry out statistical analysis of the data. All experiments were independently repeated three times. The results of *in vitro* experiments were presented as mean ± SD, and the results of all *in vivo* experiments were expressed as mean ± SEM. Comparisons between groups were conducted using Student's t test or one-way ANOVA. Pearson correlation analysis was utilized for evaluate the correlation between GMEB1 and YAP1 expression in HCC tissues. The relationship between GMEB1 expression and the clinicopathological characteristics of HCC patients was assessed by the Chi-square test. $P < 0.05$ was considered a statistically significant difference between groups.

**RESULTS**

**GMEB1 is up-regulated in HCC tissues and cells**

To investigate GMEB1 expression in HCC, we analyzed GMEB1 expression in HCC through the StarBase database (http://starbase.sysu.edu.cn/), and it was unveiled that GMEB1 is aberrantly upregulated in HCC tissue samples (Figure 1A). Furthermore, we performed another database analysis of GMEB1 expression level in different subtypes of hepatocellular carcinoma (https://ualcan.path.uab.edu/), and the results revealed that GMEB1 expression was still significantly higher in HCC than in normal liver tissues (Supplementary Figure 1A). Interestingly, GMEB1 expression was further upregulated with the increasing tumor stage (Supplementary Figure 1B), tentatively suggesting a correlation between high GMEB1 expression and poorer liver cancer stage. Subsequently, we validated results from the database on clinical samples. IHC was adopted to detect GMEB1 expression in 55 selected HCC patients’ cancer tissues and corresponding para-cancer tissues. Statistical analysis manifested that GMEB1 expression in the cancerous tissues of HCC patients was significantly higher as opposed
to the para-cancer tissues (Figure 1B). Additionally, qRT-PCR analysis found that GMEB1 mRNA was markedly upregulated in HCC tissues and cells (HepG2, HCCLM3, MHCC97H and Huh7) as against para-cancerous tissues or the HL-7702 cell line (Figure 1C&D). Western blot analysis manifested that relative to HL-7702 cells, the GMEB1 protein level in HCC cells was remarkably elevated (Figure 1E).

Due to the high expression of GMEB1 in HCC tissues, we further explored the association between GMEB1 expression level and patient prognosis through the database analysis. The results from StarBase database suggested that high GMEB1 expression was linked to HCC patients’ short overall survival (Figure 1F). At the same time, the overall survival of patients with the same stage of hepatocellular carcinoma was significantly longer in patients with low GMEB1 expression compared to those with high GMEB1 expression (Supplementary Figure 1C). Chi-square test revealed that high GMEB1 expression was related to advanced TNM stage and large tumor size in HCC patients (Table 1). These results indicated that GMEB1 is highly expressed in HCC tissues and that upregulation of GMEB1 expression is strongly associated with an exacerbation of the malignant phenotype and poor prognosis. Also, this section provisionally suggested that the upregulation of GMEB1 may play a role in the malignant progression of hepatocellular carcinoma.

**GMEB1 facilitates HCC cell multiplication, migration and invasion, and suppresses cell apoptosis**

To delve into the biological function of GMEB1 in HCC cells, we transfected HepG2 cells with pcDNA-GMEB1 to construct the GMEB1 overexpression cell model, and transfected Huh7 cells with si-GMEB1#1 or si-GMEB1#2 to construct the GMEB1 knockdown cell model. Western blot analysis showed that the plasmids were successfully transfected into cells, which was reflected in the results that GMEB1 was successfully overexpressed in HepG2 cells while GMEB1 was effectively silenced and down-regulated in Huh7 cells (Figure 2A). Next, to investigate the effect of GMEB1 on the proliferation of hepatocellular carcinoma cells, CCK8 assay was performed to assess
the alteration in cell viability and proliferation rate following changes in GMEB1 expression levels. Results from CCK-8 assay demonstrated that overexpression of GMEB1 significantly promoted the proliferation of HepG2 cells while GMEB1 knockdown dramatically inhibited the proliferation of Huh7 cells compared to the si-NC group (Figure 2B). Furthermore, we continued to examine the effect of altered GMEB1 expression levels on cellular apoptosis in different groups by flow cytometry, and analysis of the PI/Annexin V double staining results showed that the percentage of apoptotic cells increased substantially after GMEB1 silencing, while the percentage of apoptotic cells in the overexpression group decreased markedly compared to the control group, suggesting that GMEB1 could enhance the anti-apoptotic ability of cells and promote cell survival (Figure 2C and D). The above results indicated that GMEB1 had a remarkable promotion effect on the growth of hepatocellular carcinoma cells, which was mainly achieved through the dual effect on inhibiting apoptosis and promoting proliferation.

In addition to promoting proliferation, we’d also like to know whether GMEB1 could alter the migration and invasion ability of hepatocellular carcinoma cells as well. The UALCAN database was firstly employed to analyze the correlation between GMEB1 and nodal metastasis status. As we can see in Supplementary Figure 1D, with the increase of nodal metastasis status, the expression level of GMEB1 was boosted as well. In order to further verify this conjecture, we conducted Transwell assay. The results indicated that overexpression of GMEB1 significantly promoted the migration and invasion of HepG2 cells, while knockdown of GMEB1 strongly inhibited the motor ability of Huh7 cells, suggesting that GMEB1 also plays an important role in promoting the migration and invasion ability of hepatocellular carcinoma cells and increasing the metastatic potential of tumors (Figure 2E-H).

Taken together, we can easily infer that GMEB1 can enhance the proliferation and anti-apoptotic ability of tumor cells, thus promoting unlimited proliferation of tumor. In addition, the enhancement of the migration and invasion ability of tumor cells further increases the possibility of tumor metastasis.
GMEB1 binds to the YAP1 promoter to promote transcription of YAP1

The next question is how GMEB1 promotes malignant proliferation and invasion of hepatocellular carcinoma cells and what are the downstream target genes, which we will then explore in more depth. Firstly, we analyzed the JASPAR databases (http://jaspar.genereg.net/) and found that GMEB1 may bind to three sites in the promoter region of YAP1 (Figure 3A). The StarBase database (http://starbase.sysu.edu.cn/) showed that GMEB1 and YAP1 expression are positively correlated in hepatic cancer tissue samples (Figure 3B). To verify the relationship between GMEB1 and YAP1, we then constructed wild-type plasmids with YAP1 promoter binding region and plasmids with mutations in the predicted binding sites, and then transfected cells with plasmids separately and collected them for dual luciferase reporter gene assays. The results revealed that overexpression of GMEB1 enhanced the luciferase activity of YAP1-WT in HepG2 cells, whereas GMEB1 knockdown reduced the luciferase activity of YAP1-WT in Huh7 cells (Figure 3C); neither GMEB1 overexpression nor knockdown had any significant effect on the luciferase activity of YAP1-MUT (Figure 3C), suggesting that GMEB1 can specifically bind to the YAP1 promoter region, and the binding site predicted by the database is the region where GMEB1 binds to the YAP1 promoter, and GMEB1 can positively regulate YAP1 expression at the transcriptional level. Moreover, ChIP-qPCR analysis demonstrated that GMEB1 was markedly enriched in the promoter region of YAP1 compared to the IgG control (Figure 3D), further confirming that GMEB1 directly regulates the transcriptional activation of YAP1. To this end, we examined the effects of altered GMEB1 expression on YAP1 at the mRNA and protein levels, respectively, and found that overexpression of GMEB1 promoted YAP1 expression in HepG2 cells, whereas knockdown of GMEB1 inhibited YAP1 expression in Huh7 cells (Figure 3E-F). In addition, we also examined the expression of YAP1 in HCC tissues. qRT-PCR results illustrated that the expression of YAP1 mRNA was much higher in HCC tissues than in...
para-cancerous tissues (Figure 3G); Pearson analysis indicated that GMEB1 mRNA was positively correlated with YAP1 mRNA expression in HCC tissues (Figure 3H).

**GMEB1 boosts HCC cell multiplication, migration and invasion and suppresses cell apoptosis through targeting YAP1**

To verify the effect of GMEB1/YAP1 regulatory circuit on proliferation, migration, invasion and apoptosis of HCC cells, we co-transfected HepG2 cells with pcDNA-GMEB1 and si-YAP1; co-transfected Huh7 cells with si-GMEB1#1 and pcDNA-YAP1, respectively. qRT-PCR and Western blot assays illustrated that GMEB1 overexpression and YAP1 protein silencing were successful (Figure 4A and B). The results of CCK-8 assay, Transwell and flow cytometry demonstrated that the promotion of proliferation, migration and invasion as well as the anti-apoptotic effect of GMEB1 overexpression on HepG2 cells was reversed by the knockdown of YAP1; on the other hand, the upregulation of YAP1 also reversed the effect of knockdown of GMEB1 on the proliferation, migration, invasion and anti-apoptotic effect of YAP1 on Huh7 cells (Fig 4C-F).

To further validate this effect, we then constructed sh-GMEB1, oe-YAP1 and sh-GMEB1+oeYAP1 stable expression cell lines by lentiviral infection and investigated the effect of the GMEB1/YAP1 regulatory loop on tumor proliferation by Cell-derived xenografts (CDX) model in nude mice. The results revealed that sh-GMEB1 remarkably slowed down the proliferation rate of HepG2-derived xenografts, whereas overexpression of YAP1 significantly enhanced the proliferation ability of tumors compared with the oe-NC group. More interestingly, silencing GMEB1 followed by overexpression of YAP1 markedly reversed the proliferation inhibitory effect of silencing GMEB1 (Figure 5A and B). The above data suggested that the GMEB1/YAP1-regulated signaling axis can effectively increase the level of malignant proliferation of tumor. Subsequently, we examined whether the number of HCC metastasis foci forming in the lung would be altered by tail vein injection of the above cells. As we can see, silencing of GMEB1 significantly reduced the number of metastatic foci, whereas
overexpression of YAP1 did the opposite. Furthermore, silencing of GMEB1 followed by overexpression of YAP1 also reversed the inhibitory effect of GMEB1 silencing on the metastatic ability, with no significant difference from the control group (Figure 5C and D). Taken together, these data further confirmed our findings at the cellular level from the perspective of CDX mice model and emphasized the positive regulation of the GMEB1/YAP1 signaling axis on the malignant proliferation and metastasis of hepatocellular carcinoma.

**DISCUSSION**

Transcription factors are a major type of DNA-binding protein that regulates gene expression via binding with specific DNA sequences in gene promoter regions, thereby affecting cell growth, differentiation and apoptosis[29,30]. Many studies have shown that transcription factors can partake in regulating HCC occurrence and development. For instance, the transcription factor FOXN3 is downregulated in HCC and can inhibit cancer cell proliferation via negatively regulating E2F5 expression[31]; the transcription factor ATF3 suppresses HCC cell metastasis and proliferation by upregulating CYR61 expression[32]; the transcription factor KLF5 boosts HCC cell multiplication and metastasis by activating the PI3K/AKT/Snail signal pathway[33]. GMEB1 is a glucocorticoid regulatory element-binding protein, a ubiquitous multifunctional DNA-binding protein, and a transcription factor, which features prominently in the modulation of transcription after steroid hormone activation[34,35]. For the first time, this study discovered that GMEB1 was up-regulated in HCC tissues and cells. High GMEB1 expression was correlated to the advanced TNM stage, relatively large tumor size, and relatively short overall survival time of HCC patients. *In-vitro* functional research indicated that GMEB1 overexpression facilitated HCC cell multiplication, migration and invasion, and repressed the apoptosis, yet knocking down GMEB1 resulted in the opposite effects. This demonstrates that GMEB1 plays a vital role in the malignant progression of HCC.
In the further mechanism study, we mainly focused on the exploration for the downstream target gene of GMEB1, and finally determined that YAP1 was a new downstream target gene of GMEB1 through database prediction and experimental verification. YAP1, located on human chromosome 11q22, is a transcriptional coactivator of the Hippo pathway, and it modulates the transcription of downstream target genes and intracellular signal transduction through phosphorylation, thus maintaining the balance of cell multiplication and apoptosis\cite{36}. Some studies have found that YAP1 is targeted and regulated by multiple microRNAs (miRs), such as miR-506\cite{37}, miR-200a\cite{38}, miR-139-5p\cite{39} and miR-27b-3p\cite{40}. Reportedly, YAP1 is abnormally high-expressed in various tumor tissues, and participates in facilitating tumor cell multiplication, invasion and migration and the activation of multiple signaling pathways\cite{36,38,41,42}. For example, YAP1 is up-regulated in bladder carcinoma tissues and can interact with mTOR protein to promote bladder carcinoma cell proliferation\cite{43}. The increase in YAP1 expression is connected with the poor prognosis of BC patients, and inhibits PTEN expression to boost BC cell multiplication and repress the apoptosis\cite{44}. In HCC, YAP1 can facilitate cell proliferation, invasion and EMT process in vitro\cite{45}. In our study, we first found that GMEB1 could bind with the YAP1 promoter region and could positively modulate YAP1 expression in HCC cells. Also, there was a positive correlation between YAP1 and GMEB1 expression in HCC tissues. Moreover, alteration of YAP1 expression could mediate GMEB1-induced HCC cell multiplication, migration, invasion and apoptosis.

The crucial role of the Hippo signaling pathway, with YAP/TAZ as the main effector proteins, in the development of hepatocellular carcinoma has been confirmed and highlighted by numerous studies\cite{46}, however, no inhibitors directly targeting core proteins of the Hippo signaling pathway have been successfully marketed, making direct intervention of the Hippo signaling pathway difficult and preventing patients with excessive Hippo activation from benefiting more from conventional therapies. For this reason, a number of studies have begun to attempt to interfere with the Hippo signaling pathway through the inhibition of indirectly regulated proteins. These include PFI-2, a highly selective inhibitor of SETD7 methyltransferase, which inhibits YAP
nuclear translocation and Hippo pathway activation through direct interaction with SETD7[47], and Ki-16425, a competitive inhibitor of LPA1/2/3, which inhibits Hippo signaling by blocking LPA receptor-induced YAP/TAZ dephosphorylation[48]. The discovery of our study further enriches the range of target options for indirect intervention in the Hippo signaling pathway, thus providing new candidate proteins for inhibitor development.

**CONCLUSION**

In conclusion, our study revealed for the first time that GMEB1 is highly expressed in both HCC tissues and cells. Furthermore, we confirmed that YAP1 is a novel transcriptional target gene of GMEB1 and demonstrated that GMEB1/YAP1 regulatory axis has a key role in promoting HCC cell proliferation, migration and invasion and anti-apoptosis. As this suggests that, on the one hand, GMEB1 can be a candidate molecular marker for accurate diagnosis of early-stage liver cancer; on the other hand, targeting GMEB1 may be a potential therapeutic approach to improve the efficiency of HCC treatment. However, our study also has some limitations. Firstly, we only used the CDX animal model to verify the regulation of GMEB1 on the malignant progression of HCC; we lacked samples from clinical sources for further corroboration. In addition, we lacked follow-up studies on patients so as to further corroborate the effect of GMEB1 on the prognosis of hepatocellular carcinoma. In subsequent studies, we will continue to refine our findings in the follow-up study and continue to obtain more reliable experimental conclusions.

**ARTICLE HIGHLIGHTS**

Research background

Most hepatocellular carcinoma (HCC) cases have already been in an intermediate to advanced stage at diagnosis, missing the optimal time for surgical treatment. Besides, the high cost and huge shortage of donors greatly limit the clinical application of liver transplantation. Therefore, the lack of reliable diagnostic markers and interventions
makes the overall survival rate of HCC patients hardly improved, and the prognosis of patients is generally poor.

**Research motivation**
Mechanistic understanding of proliferation promotion, increased metastatic potential and cellular defense against apoptosis can inform novel therapeutic strategies in HCC treatment. We would like to clarify the biological functions and clinical significance of glucocorticoid modulatory element-binding protein 1 (GMEB1) in HCC to provide more reliable biomarkers and target candidates for HCC diagnosis and treatment.

**Research objectives**
Due to the lack of reliable early diagnosis biomarkers and clinical intervention targets, patients with HCC are often diagnosed in the middle and late stages with poor prognosis. This study aims to find new molecular biomarkers with high reference value and effective candidate targets for the treatment of HCC.

**Research methods**
GMEB1 expression level was detected through bioinformatics analysis first and further validation was conducted in HCC clinical tissue samples by using immunohistochemistry and qPCR; immunoblotting and qPCR were used to detect the expression of GMEB1 in HCC cell lines. Cell counting kit-8 assay, Transwell and flow cytometry were performed to assess the alteration on proliferation and metastasis potential of HCC cells after changes on GMEB1 expression level in HCC cell lines. The binding site of GMEB1 to Yes-associate protein 1 (YAP1) promoter was predicted by bioinformatics analysis and verified by dual luciferase reporter gene assay and ChIP-qPCR.

**Research results**
GMEB1 was abnormally highly expressed in HCC, whose expression correlates with some clinicopathological features of HCC patients, such as tumor size and TNM stage. According to in vitro results, overexpression of GMEB1 promotes the malignant proliferation and metastasis of HCC cell lines, while knockdown of GMEB1 suppresses the degree of malignancy. In mechanism, GMEB1 positively regulates the expression of YAP1 in transcription level, which finally promote the progression of HCC.

Research conclusions
GMEB1 is a new oncogenic factor of HCC, which promotes the malignant proliferation and metastasis of HCC by promoting YAP1 transcriptional activation.

Research perspectives
This study reveals that GMEB1, a member of KDWK gene family to modulate the transactivation of the glucocorticoid receptor, has a previously unrecognized role in HCC progression, suggesting that it may be a promising biomarker for early-stage HCC diagnosis and it is possible to intervene in anti-tumor therapy against HCC by inhibiting GMEB1-mediated tumor proliferation, metastasis and anti-apoptosis effect.

REFERENCES


10 Kawabe K, Lindsay D, Braitch M, Fahey AJ, Showe L, Constantinescu CS. IL-12 inhibits glucocorticoid-induced T cell apoptosis by inducing GMEB1 and activating
PI3K/Akt pathway. *Immunobiology* 2012; 217: 118-123 [PMID: 21840619 DOI: 10.1016/j.imbio.2011.07.018]


16 Shibata M, Ham K, Hoque MO. A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy. *Int J Cancer* 2018; 143: 2133-2144 [PMID: 29696628 DOI: 10.1002/ijc.31561]


YAP1 converge to regulate EMT and tumor survival. *Cell* 2014; **158**: 171-184 [PMID: 24954536 DOI: 10.1016/j.cell.2014.06.004]


48 **Ueda H**, Neyama H, Sasaki K, Miyama C, Iwamoto R. Lysophosphatidic acid LPA(1) and LPA(3) receptors play roles in the maintenance of late tissue plasminogen activator-induced central poststroke pain in mice. *Neurobiol Pain* 2019; **5**: 100020 [PMID: 31194070 DOI: 10.1016/j.ynpai.2018.07.001]
Hai-Yan Fu, Qiu-Hong Wang, Hong-Juan Li, Jian-Peng Gao, Li Liu, Bo Tang, Dong Wei, Bin Xu, Xin Tong, Jie Li, Yu Luo. "Partition defective 3 promotes TAZ nuclear localization and promotes Amphiregulin transcription to promote liver hepatocellular carcinoma cell invasion, migration and epithelial mesenchymal", Research Square Platform LLC, 2022
Crossref Posted Content
<table>
<thead>
<tr>
<th></th>
<th>Author(s)</th>
<th>Title</th>
<th>Journal</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>M Z Xu</td>
<td>&quot;AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma&quot;</td>
<td>Oncogene</td>
<td>2010</td>
</tr>
<tr>
<td>9</td>
<td>Tiago Biachi de Castria, Danny N Khalil, James J Harding, Eileen M O'Reilly, Ghassan K Abou-Alfa</td>
<td>&quot;Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma&quot;</td>
<td>Future Oncology</td>
<td>2022</td>
</tr>
<tr>
<td>10</td>
<td>Jian Kang, Xu Huang, Weiguo Dong, Xueying Zhu, Ming Li, Ning Cui</td>
<td>&quot;Long non-coding RNA LINC00630 facilitates hepatocellular carcinoma progression through recruiting transcription factor E2F1 to up-regulate cyclin-dependent kinase 2 expression&quot;</td>
<td>Human &amp; Experimental Toxicology</td>
<td>2021</td>
</tr>
<tr>
<td>11</td>
<td>Guo, Yan, Qiao Pan, Jing Zhang, Xinyuan Xu, Xiping Liu, Qinhao Wang, Ru Yi, Xiaobo Xie, Libo Yao, Wenchao Liu, and Lan Shen</td>
<td>&quot;Functional and Clinical Evidence that TAZ is a Candidate Oncogene in Hepatocellular Carcinoma&quot;</td>
<td>Journal of Cellular Biochemistry</td>
<td>2015</td>
</tr>
</tbody>
</table>

Crossref

Internet

www.ijcep.com

www.pubfacts.com


Min Feng, Ningfei Dong, Xin Zhou, Lihong Ma, Rui Xiang. "Myosin light chain 9 promotes the proliferation, invasion, migration and angiogenesis of colorectal cancer cells by binding to Yes-associated protein 1 and regulating Hippo signaling", Bioengineered, 2022

Shehua Qian, Xiaohan Zhan, Miaolong Lu, Na Li, Ying Long, Xuejun Li, Dominic M. Desiderio, Xianquan Zhan. "Quantitative Analysis of Ubiquitinated Proteins in Human Pituitary and Pituitary Adenoma Tissues", Frontiers in Endocrinology, 2019

Zhi Cui, Qiong Sun, Wenji Yan, Quanli Han, Guanjun Wang, Yi Hu. "The role of miR-320a and its target gene in epithelial-mesenchymal transition and invasion of colorectal cancer", The Journal of Gene Medicine, 2021
Yi Zhou, Jiangxue Wu, Xiang Fu, Wuying Du et al. "OTUB1 promotes metastasis and serves as a marker of poor prognosis in colorectal cancer", Molecular Cancer, 2014

oaji.net

www.frontiersin.org